A Study of AMX-883 in People With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Full Title

A Phase 1, Open-Label, Multi-Centre Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of AMX-883 Monotherapy in Participants with Acute Myeloid Leukaemia and High-Risk Myelodysplastic Syndrome and in Combination with Anticancer Agents in Participants with Acute Myeloid Leukaemia

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Eytan Stein’s office at 646-608-3749.

Protocol
26-358
Phase
Phase I (phase 1)
Investigator
Eytan M. Stein
Co-Investigators
Kuo-Kai Chin
Diseases
Leukemia › Acute Myelocytic Leukemia
Leukemia › Acute Myelogenous Leukemia
Leukemia › Myelodysplastic Syndrome
Locations
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Commack Nonna’s Garden Foundation Center
Memorial Sloan Kettering Basking Ridge
Memorial Sloan Kettering Westchester
Memorial Sloan Kettering Monmouth
Memorial Sloan Kettering Bergen
Memorial Sloan Kettering Nassau
ClinicalTrials.gov ID
NCT07723703
ClinicalTrials.gov
Visit ClinicalTrials.gov for full clinical trial description